clinical trial · NCT06203002
A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
Diabetic Peripheral Neuropathic PainPlacebo (blinded)LX9211 (blinded)
brief summary
Evaluation of the efficacy of LX9211 compared to placebo in reducing DPNP. Please see study website: https://diabeticpainstudy.com/
started
Nov 29, 2023
primary completion
Jan 14, 2025
completion
Feb 24, 2025
last updated
Oct 10, 2025
official title
A Phase 2b, Dose-ranging, Randomized, Double-blind, PlacebO-controlled, Parallel-GRoup, MulticEnter Study in PatientS With Diabetic Peripheral Neuropathic Pain (PROGRESS)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol